Ratings Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:01 2023-12-01 pm EST			5-day change	1st Jan Change
50.10 ^USD	+1.46%		+0.68%	-30.37%

Dec. 01	Bristol Myers Squibb Insider Bought Shares Worth $150,049, According to a Recent SEC Filing	MT
Nov. 29	US FDA investigating safety risk of CAR-T cancer therapies	RE

Summary

The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
The company is one of the best yield companies with high dividend expectations.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
BRISTOL-MYERS SQUIBB COMPANY	-30.37%	102 B $	B
ELI LILLY AND COMPANY	+59.64%	525 B $	C+
NOVO NORDISK A/S	+48.98%	454 B $	B
JOHNSON & JOHNSON	-10.34%	381 B $	C+
MERCK & CO., INC.	-6.75%	262 B $	B-
ABBVIE INC.	-11.26%	253 B $	C+
ROCHE HOLDING AG	-17.52%	221 B $	A+
NOVARTIS AG	+2.14%	202 B $	B-
ASTRAZENECA PLC	-9.09%	200 B $	B+
PFIZER, INC.	-43.58%	163 B $	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes